Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04670445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04670445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Completed
Start date
January 23, 2021
Completion date
April 1, 2024
Enrollment
199 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung cancer, immune checkpoint inhibitors, immunotherapy, small cell lung cancer extensive stage, stage iv basal cell carcinoma, stage iv bladder cancer, stage iv breast cancer, stage iv cervical cancer, stage iv colorectal cancer, stage iv cutaneous squamous cell carcinoma, stage iv endometrial cancer, stage iv esophageal cancer, stage iv gastric cancer, stage iv head and neck squamous cell carcinoma, stage iv hepatocellular cancer, stage iv melanoma, stage iv merkel cell carcinoma, stage iv mesothelioma, stage iv non-small cell lung cancer, stage iv renal cell carcinoma, unresectable non-small cell lung carcinoma, unresectable stage iii non-small cell lung cancer